Generex Biotechnology (Generex Biotechnology) Cash Flow from Financing : $3.64 Mil (TTM As of Apr. 2021)

View and export this data going back to 1998. Start your Free Trial

What is Generex Biotechnology Cash Flow from Financing?

Cash from financing is the cash generated/spent from financial activities such as share issuance (buy back), debt issuance (repayment), and dividends paid to preferred and common stockholders.

For the three months ended in Apr. 2021, Generex Biotechnology received $0.69 Mil more from issuing new shares than it paid to buy back shares. It spent $0.19 Mil paying down its debt. It paid $0.00 Mil more to buy back preferred shares than it received from issuing preferred shares. It received $0.00 Mil from paying cash dividends to shareholders. It spent $0.00 Mil on other financial activities. In all, Generex Biotechnology earned $0.50 Mil on financial activities for the three months ended in Apr. 2021.

Generex Biotechnology Cash Flow from Financing Historical Data

The historical data trend for Generex Biotechnology's Cash Flow from Financing can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Generex Biotechnology Cash Flow from Financing Chart

Generex Biotechnology Annual Data

Trend

Jul11

Jul12

Jul13

Jul14

Jul15

Jul16

Jul17

Jul18

Jul19

Jul20

Cash Flow from Financing

Get a 7-Day Free Trial

0.05

4.04

0.45

6.51

5.81

Generex Biotechnology Quarterly Data
	Jul16	Oct16	Jan17	Apr17	Jul17	Oct17	Jan18	Apr18	Jul18	Oct18	Jan19	Apr19	Jul19	Oct19	Jan20	Apr20	Jul20	Oct20	Jan21	Apr21
Cash Flow from Financing	Get a 7-Day Free Trial															1.02	0.25	2.16	0.74	0.50

Generex Biotechnology Cash Flow from Financing Calculation

This is the cash generated/spent from financial activities such as share issuance (buy back), debt issuance (repayment), and dividends paid to preferred and common stockholders. In the calculation of free cash flow, cash from financing is not calculated because it is not related to operating activities.

Generex Biotechnology's Cash from Financing for the fiscal year that ended in Jul. 2020 is calculated as:

	Cash Flow from Financing		(A: Jul. 2020 )
=	Issuance of Stock	+	Repurchase of Stock	+	Net Issuance of Debt	+	Net Issuance of Preferred Stock	+	Cash Flow for Dividends	+	Other Financing
=	0.11	+	0	+	5.701	+	0	+	0	+	-0.001
=	5.81

Generex Biotechnology's Cash from Financing for the quarter that ended in Apr. 2021 is:

	Cash Flow from Financing		(Q: Apr. 2021 )
=	Issuance of Stock	+	Repurchase of Stock	+	Net Issuance of Debt	+	Net Issuance of Preferred Stock	+	Cash Flow for Dividends	+	Other Financing
=	0.69	+	0	+	-0.187	+	0	+	0	+	-0.001
=	0.50

Cash Flow from Financing for the trailing twelve months (TTM) ended in Apr. 2021 adds up the quarterly data reported by the company within the most recent 12 months, which was $3.64 Mil.

Generex Biotechnology (OTCPK:GNBTQ) Cash Flow from Financing Explanation

Cash from financing contains six items:

1. Issuance of Stock:
A company may raise cash from issuing new shares. Issuance of stock represents the cash inflow from offering common stock, which is the additional capital contribution to the entity during the period.

Generex Biotechnology's issuance of stock for the three months ended in Apr. 2021 was $0.69 Mil.

2. Repurchase of Stock:
A company may raise cash from issuing new shares. It can also use cash to buy back shares. Repurchase of stock represents the cash outflow to reacquire common stock during the period.

Generex Biotechnology's repurchase of stock for the three months ended in Apr. 2021 was $0.00 Mil.

3. Net Issuance of Debt:
Net issuance of debt is the cash a company received or spent through debt related activities such as debt issuance or debt repayment. If a company pays down its debt during the period, this number will be negative. If a company issued more debt, it receives cash and this number is positive.

Generex Biotechnology's net issuance of debt for the three months ended in Apr. 2021 was $-0.19 Mil. Generex Biotechnology spent $0.19 Mil paying down its debt.

4. Net Issuance of Preferred Stock:
A company may raise cash from issuing new preferred shares. It can also use cash to buy back preferred shares. If this number is positive, it means that the company has received more cash from issuing preferred shares than it has paid to buy back preferred shares. If this number is negative, it means that company has paid more cash to buy back preferred shares than it has received for issuing preferred shares.

Generex Biotechnology's net issuance of preferred for the three months ended in Apr. 2021 was $0.00 Mil. Generex Biotechnology paid $0.00 Mil more to buy back preferred shares than it received from issuing preferred shares.

5. Cash Flow for Dividends:
Cash flow for dividends refers to the payment of cash to shareholders as dividends when the company generates income.

Generex Biotechnology's cash flow for dividends for the three months ended in Apr. 2021 was $0.00 Mil. Generex Biotechnology received $0.00 Mil from paying cash dividends to shareholders.

6. Other Financing:
Money spent or earned by company from other financial activities.

Generex Biotechnology's other financing for the three months ended in Apr. 2021 was $-0.00 Mil. Generex Biotechnology spent $0.00 Mil on other financial activities.

Generex Biotechnology Cash Flow from Financing Related Terms

Thank you for viewing the detailed overview of Generex Biotechnology's Cash Flow from Financing provided by GuruFocus.com. Please click on the following links to see related term pages.

Generex Biotechnology (Generex Biotechnology) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Generex Biotechnology Corp (OTCPK:GNBTQ) » Definitions » Cash Flow from Financing

Comparable Companies

RBSH MRPI BOM:531207 HSTC PPCB NUGX BOM:506365 CDXI IMUN RSPI

Traded in Other Exchanges

N/A

Address

10102 USA Today Way, Miramar, FL, USA, 33025

Website

https://www.generex.com

Generex Biotechnology Corp is a Biotechnology company which is primarily engaged in the research and development of drug delivery systems and technologies. It mainly focuses on developing technology for the administration of formulations of large molecule drugs to the oral (buccal) cavity using a hand-held aerosol applicator. The company operates in the single segment being the Research and development of drug delivery systems and technologies for metabolic and immunological diseases. In addition, the company engages in developing proprietary vaccine formulations through its subsidiaries that work by stimulating the immune system to either attack offending agents that is cancer cells, bacteria, and viruses or to stop attacking benign elements.

Executives

Prioletti Mark Joseph Se	director	1121 PALMER COURT CRYSTAL LAKE IL 60014
Salvo Lawrence Anthony Sr	director	450 ALTON ROAD APT 3704 MIAMI BEACH FL 33139
Harold Gray Haines	other: Consultant	11511 SW 127TH ST MIAMI FL 33176
Mark Fletcher	officer: EVP General Counsel &Secretary	4145 NORTH SERVICE ROAD, SUITE 200 BURLINGTON A6 L7L6A3
Brian Mcgee	director	201 BRIDGELAND AVE TORONTO ONTARIO CANDA M6A 1Y7 A6 00000
Anderson James H Jr.	director	33 HARBOUR SQUARE TORONTO A6 M5J2G2
Mark Corrao	officer: CFO & Treasurer	531 AIRPORT NORTH OFFICE PARK, FORT WAYNE IN 46825
Purcell Richard David Jr.	director, officer: SVP of Research & Drug Develop	65 FAIR HAVEN ROAD, FAIR HAVEN NJ 07704
Gary Herbert Lyman	director	10102 USA TODAY WAY MIRAMAR FL 33025
Kevin Centofanti	director	10102 USA TODAY WAY MIRAMAR FL 33025
Andrew Ro	director, officer: SVP & Chief Investment Officer	10102 USA TODAY WAY MIRAMAR FL 33025
David Brusegard	officer: Chief Operating Officer	4145 NORTH SERVICE ROAD, SUITE 200 BURLINGTON A6 L7L6A3
Stephen Fellows	officer: Chief Financial Officer	33 HARBOUR SQUARE SUITE 202 TORONTO A6 M5J 2G2
Hofe Eric Von	director, officer: President of Subsidiary	4145 NORTH SERVICE ROAD, SUITE 200 BURLINGTON A6 L7L6A3
John P Barratt	director	555 RICHMOND ST. W, SUITE 604 TORONTO A6 M5V3B1